

RESEARCH ARTICLE

Open Access



# Normality data of eGFR and validity of commonly used screening tests for CKD in an area with endemic CKD of unknown etiology; need for age and sex based precise cutoff values

Nalaka Herath<sup>1</sup>, Rajeewa Dassanayake<sup>1</sup>, Manjula Dissanayake<sup>1</sup>, Chamara Janitha<sup>2</sup>, Kosala Weerakoon<sup>3</sup>, Chalaka Kumarasinghe<sup>1</sup>, Terence Gamini de Silva<sup>1</sup> and Suneth Agampodi<sup>4\*</sup> 

## Abstract

**Background:** Chronic Kidney Disease in certain part of Sri Lanka and increasing burden of CKD in some other countries is a global public health problem. While the underlying causes of majority of cases are unknown, effective control and prevention strategies are yet to be taken. Though the disease has been identify more than decade ago, baseline data on renal function are not available. This study reports the age and sex disaggregated data of renal functions among screening participants of the Anuradhapura, the district with the highest disease burden in Sri Lanka.

**Methods:** The screening programme was done as a part of CKD control programme of Anuradhapura. All screening centers were visited and information and urine sample collection tubes were distributed before the screening date. A serum and urine sample was taken from all participants. In a subsample, urine sulfosalicylic acid test (SSA Test), urine dipstick test, urine albumin to creatinine ratio (UACR) and urine protein to creatinine ratio (UPCR) was done.

**Results:** The study sample included 7768 apparently healthy people aging 18 to 93 years and females ( $n = 5522$ ) accounted for 71.1% of the sample. Mean age of the participants was 45.9 (SD 14.1) years. Mean eGFR in this population was 90.8 mL/min/1.73m<sup>2</sup>(SD 24.6) with a significantly lower eGFR (88.1 mL/min/1.73m<sup>2</sup>) among males compared to female (92.8 mL/min/1.73m<sup>2</sup>). Mean eGFR was 115 mL/min/1.73m<sup>2</sup> (SE .5) among participants aging less than 30 and this value drastically reduced to 59.1 mL/min/1.73m<sup>2</sup> (SE 1.2) among people aging more than 70 years. Proportion of people having reduction of eGFR compatible with mild, moderate, severe and kidney failure categories was 33.9(32.7–34.8), 8.4(7.8–9.0), 1.5(1.2–1.7) and 0.7(0.5–0.9). The age and sex adjusted prevalence of eGFR less than 60 mL/min/1.73 m<sup>2</sup> in a single sample in this population was 10.6%. Bayesian Latent Class model analysis shows that UPCR > 150 has the highest sensitivity to detect those who are with eGFR less than 60 mL/min/1.73 m<sup>2</sup>. UACR, the usual recommended test as a screening test was having a sensitivity of 35.3% in this population.

**Conclusion:** UPCR and UACR should be use as a screening tests in areas with high proportion of CKDu patients. More research are required to investigate the use of age and sex specific cut off values to diagnose CKD.

**Keywords:** CKD, CKDu, eGFR, Sri Lanka, Anuradhapura, Baseline values, Screening, UACR, UPCR

\* Correspondence: [sunethagampodi@yahoo.com](mailto:sunethagampodi@yahoo.com)

<sup>4</sup>Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka  
Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

## Background

Chronic kidney disease (CKD) has become a major public health problem worldwide [1]. Epidemiological studies of the adult population in several countries report varying degree of CKD prevalence with 9–11% in United States (US) [2], 9.1% in Spain [3], and 10.6% in Netherlands [4]. CKD prevalence increases with age, and is highest after the age of 60 years [2–4]. There is a regional variation in CKD is reported in several studies, which is attributed to socio demographics risk factors [5].

From the 1990s, an increase in CKD prevalence [2, 3, 6–8] and emergence of a CKD of unknown etiology (CKDu) was observed in several countries including El Salvador, Nicaragua, Costa Rica, Sri Lanka [9–11], Egypt [12] and India [13]. CKDu is usually asymptomatic until advanced disease. Clinically, CKDu is characterized by minimal or no urinary abnormalities due to chronic interstitial nephropathy, which has been confirmed by renal biopsies in Costa Rica, El Salvador and Sri Lanka [11].

The prevalence and associated mortality of CKD has been on the rise in Sri Lanka [8]. Exact prevalence of CKD in Sri Lanka is largely unknown, mainly due to the unavailability of renal registries and lack of epidemiological studies. However, population screening in Sri Lanka shows variable prevalence in different districts [8]. The prevalence of CKDu was 15.1% in Anuradhapura, 20.6% in Polonnaruwa and 22.9% in Badulla [8]. While the screening tests are in process, baseline data on the population estimated glomerular filtration rate (eGFR) distribution and age, sex disaggregated data on eGFR for Sri Lanka is not available in published literature. For clinical practice as well as for public policy, assessment of baseline eGFR is recommended. Planning of screening programmes, determining age and sex specific cut off points as well as public health programme planning should ideally be based on these baseline data.

Screening of high risk people for CKD has been a standard practice worldwide [14–16]. There is no uniform screening method to be applied to detect CKD patients with all different aetiologies. Urine protein analysis or serum creatinine estimation or combination of these two has been used to detect CKD in diabetes and hypertensive patients [17]. Commonly used screening tests for abnormal protein excretion in urine includes urine sulfosalicylic acid test (SSA Test), urine dipstick test, urine albumin to creatinine ratio (UACR) and urine protein to creatinine ratio (UPCR). Urine SSA tests and dipstick analysis is used in most outpatient settings for semi quantitative measurement of urine protein concentration. UPCR and UACR measure protein excretion quantitatively and can be done on a spot urine sample. An elevated UACR (or albuminuria) is the most widely used marker for identifying kidney damage, as it is highly sensitive in the earlier stages of traditional CKD

[4]. Persistent microalbuminuria has been used to detect early CKD in diabetes and hypertensive patients. However, urine protein or microalbumin analysis may not be effective in screening of patients with CKDu.

Our study was designed to estimate the baseline eGFR values of apparently health population living in the area with highest reported prevalence of CKDu in Sri Lanka using different estimation methods and also to compare the test characteristics of different methods of proteinuria/albuminuria estimations as valid field tests.

## Methods

Present paper included two components; secondary data analysis of routine screening programme in Anuradhapura and evaluation of proteinuria based screening methods used in combination with serum creatinine. This descriptive cross-sectional study was carried out as a part of population based screening for CKD in Anuradhapura in 2015. The screening was carried out as a part of the national programme on CKD prevention. Screening clinics were held in community settings easily accessible to the catchment population on pre-determined dates with prior notification given to the target population. Participation in the screening programme was voluntary and those who are without a known history of CKD were invited to participate. For the first component of this analysis, we selected only those who are above 18 years and having done both serum creatinine and urine SSA test to detect albuminuria as a part of screening programme. In 2015, SSA test was used on a spot urine sample routinely as a part of population based screening programme in this area. For serum creatinine, a 2 mL venous blood was drawn aseptically to a plain tube (with no anticoagulants) by a registered nursing officer. Serum samples were transported to the renal laboratory at teaching hospital, Anuradhapura same day and analyzed using Dimension RxL Pro clinical chemistry analyzer (Siemens Healthcare, Erlangen, Germany) by a trained medical laboratory technologist. SSA test was performed by adding 0.25 mL of urine to 1 mL of 30% sulfosalicylic acid and this method has been validated by the laboratory. Since study participants are not representative of age and sex structure of the population, we used direct standardization to estimate the prevalence values using the Sri Lankan population data.

The second component of this analysis was to assess the utility of urine based screening tests to use in community settings as stand alone screening tests, in comparison to serum creatinine based eGFR. Some of these tests were already in use as stand alone screening tests to detect CKD in Sri Lanka. All the relevant information including urine collection technique and urine containers were distributed among people by field health workers and a group of volunteers from each village, few

days prior to the screening day. Informed written consent was obtained from all participants who participated in this additional procedure. All participants brought a morning urine sample (50 mL) using the containers provided and semi-quantitative measurement of urine protein was performed by using 2 para Uric-Techo (USA) urine strips and SSA test. Urine protein and albumin were measured by particle enhanced turbidimetric inhibition immunoassay technique and pyrogallol red method respectively on the same platform. Serum and urine creatinine assays were performed by the Jaffe method, which was traceable to isotope dilution mass spectrometry (IDMS) method, on Dimension RxL Pro clinical chemistry analyzer. Quality management was carried out appropriately including daily internal quality control runs and external quality assurance. A positive screening test was defined as having trace protein in USSA test or dipstick test, UACR > 30 mg albumin/g creatinine or UPCR > 150 mg protein/g creatinine.

eGFR was calculated using both MDRD ( $GFR \text{ (mL/min/1.73 m}^2) = 175 \times (S_{cr}/88.4)^{-1.154} \times (Age)^{0.203} \times (0.742 \text{ if female}) \times (1.212 \text{ if African American})$  (SI units)) and CKD-EPI ( $GFR = 141 \times \min(S_{cr}/\kappa, 1)^{\alpha} \times \max(S_{cr}/\kappa, 1)^{-1.209} \times 0.993^{Age} \times 1.018$  [if female]  $\times 1.159$  [if black]) equations for comparison purposes. For description of eGFR in the population, we used Kidney Disease Improving Global Outcomes (KDIGO) guideline for classification of eGFR values [17]. All those who were having abnormal eGFR were repeated in three months and confirmed before the diagnosis was made. Comparison of two equations was done. To describe normality data of eGFR for the reference population, we presented age and sex disaggregated data and a linear regression model was fitted to describe the effect of age and sex on eGFR.

For the assessment of validity, first we consider eGFR as Gold Standard. However, eGFR alone is not 100% sensitive or specific to detect CKD. To overcome the inaccurate predictions of test characteristics due to imperfect Gold Standard tests, we used Bayesian latent class model (LCM) to estimate sensitivity, specificity and predictive values of the screening tests, including eGFR as well as screening tests as covariates. The web based open access model developed by Modeling for Infectious disease Center (MICE) was used for this purpose (<http://mice.tropmedres.ac/home.aspx>). In this model, eGFR was also considered as imperfect test and model generated prevalence value (based on our inputs) were used for predictions of test validity.

Ethical clearance for the study was obtained from the Ethics Review committee of University of Peradeniya. All screen detected patients were referred to renal clinic and appropriate diagnostic tests were carried out.

## Results

The study sample included 7768 apparently healthy people aging 18 to 93 years and residing in Anuradhapura district. Females ( $n = 5522$ ) accounted for 71.1% of the sample. Mean age of the participants was 45.9 (SD 14.1) years.

eGFR based on MDRD equation showed a normal distribution and a slightly skewed distribution was observed with CKD-EPI (Fig. 1).

Comparison of two equation showed that MDRD equation was progressively overestimating the values after eGFR of around 100 mL/min/1.73m<sup>2</sup>. The highest eGFR of 307 mL/min/1.73m<sup>2</sup> in MDRD was reported as 172 mL/min/1.73m<sup>2</sup> for the same patient using CKD-EPI equation (Fig. 2).

Subsequent analysis was done using eGFR calculated with CKD-EPI.

Age and sex disaggregated data showed a steady reduction of eGFR with wider data dispersion with increasing age in both sexes (Fig. 3).

Mean eGFR was 115 (SE .5) among people aging less than 30 and this value drastically reduced to 59.1 (SE 1.2) among people aging more than 70 years.


Males had a lower eGFR value in each age category compared to females. However, this observed difference was significant only in age categories 30–39, 50–59 and 60–69 years (Table 1).

### Distribution of eGFR categories in the study sample

eGFR values were categorized according to the GFR categories for CKD staging according to KDIGO guidelines (Table 2). eGFR values compatible with moderate to severe decreased, severe decreased and kidney failure were detected among .7, 1.5 and 8.4% of the participants, totaling 10.6% prevalence of participants with eGFR value less than or equal to CKD Stage III.

Since the sample is over representing females and not representing the population structure, direct standardization was done to calculate the prevalence. For this purpose, we restricted the study population to 20–75 years age ( $n = 7450$ ), because the number of study participants below and over that age group was too small for stable age specific rates. Prevalence of CKD in this restricted population was 10.3% and the age and sex adjusted (using Sri Lankan population structure) prevalence of eGFR less than 60 mL/min/1.73 m<sup>2</sup> in this population was 10.6% (95% CI 9.9–11.3%). Estimated prevalence values for male and female populations were 12.2 and 9.2%.

Mildly decrease eGFR values were noted among 2633 (33.8, 95% CI 32.7–34.8%) of the participants. Among the latter group, urine protein (SSA method) was detected among 548 (21.4%). Progressively increasing proportions of proteinuria was detected among different categories (Table 3).



**Evaluation of urine protein based test as screening test to detect patients with abnormal eGFR**

For the evaluation of urine protein based test as screening tests, those who were having eGFR > 90 mL/min/1.73m<sup>2</sup> were considered as normal and those who are having eGFR < 60 mL/min/1.73m<sup>2</sup> were considered abnormal. We excluded all those people who were having eGFR 60–90 mL/min/1.73m<sup>2</sup> from this analysis. This was done because it will create a bias result towards screening tests, since the urine protein is an added criteria for the diagnosis of CKD those who are having eGFR in the specified range. From the second component of study, the Total number of patients available for this component was 730 with 126 patients with eGFR < 60 mL/min/1.73m<sup>2</sup>. Of the 730 selected patients, 498 (68.2%) were females. Age range was 18–85 years with a


median age of 40.6 years (SD 15.5). Performance of individual tests are shown in Table 4.


Sensitivity of UACR, UPCR, USSA and dip stick test to detect people with eGFR < 60 mL/min/1.73m<sup>2</sup> was 35.7, 59.559.2 and 25.5% respectively. Since urine dipstick method was having very low sensitivity, we further evaluated other three screening tests using the Bayesian Latent Class model (Table 5).

The test characteristics based on the Bayesian Latent Class model analysis shows that UPCR > 150 has the highest sensitivity. UACR, the usual recommended test as a screening test was having a sensitivity of 35.3% in this population.

**Discussion**

In this study, we reported the normality data on eGFR in North Central Province of Sri Lanka, to be used as





**Fig. 3** Distribution of eGFR by age and sex among 7768 screening participants on North Central Province, Sri Lanka

**Table 1** Age and sex disaggregated distribution of eGFR (CKD-EPI equation) values among 7768 apparently healthy CKD screening participants in Anuradhapura district

| Age (years) | Sex | Mean | 95.0% CL for Mean | Standard Deviation | Prevalence of eGFR < 60 mL/min/1.73 m <sup>2</sup> n | %     |     |       |
|-------------|-----|------|-------------------|--------------------|--|-------|-----|-------|
| < 30        | F   | 883  | 115.7             | 114.56             | 116.84   | 17.29 | 7   | 0.80  |
|             | M   | 291  | 112.79            | 110.52             | 115.06   | 19.66 | 4   | 1.40  |
| 30–39       | F   | 1349 | 102.32            | 101.42             | 103.22   | 16.9  | 20  | 1.50  |
|             | M   | 447  | 99.43             | 97.76              | 101.11   | 18.04 | 15  | 3.40  |
| 40–49       | F   | 1288 | 91.22             | 90.2               | 92.24  | 18.61 | 69  | 5.40  |
|             | M   | 541  | 89.57             | 87.82              | 91.32  | 20.73 | 49  | 9.10  |
| 50–59       | F   | 1236 | 81.13             | 80.03              | 82.22  | 19.67 | 167 | 13.50 |
|             | M   | 505  | 76.18             | 74.13              | 78.23  | 23.39 | 103 | 20.40 |
| 60–69       | F   | 597  | 73.57             | 72                 | 75.14  | 19.48 | 133 | 22.30 |
|             | M   | 348  | 65.73             | 63.25              | 68.2   | 23.48 | 120 | 34.50 |
| > = 70      | F   | 169  | 61.88             | 58.6               | 65.16  | 21.6  | 68  | 40.20 |
|             | M   | 114  | 55.21             | 51.55              | 58.87  | 19.7  | 66  | 72.8  |

**Table 2** Distribution of eGFR categories among 7768 apparently healthy CKD screening participants in Anuradhapura district

| eGFR level (mL/min/1.73m <sup>2</sup> ) | n    | %    | 95% confidence limits for proportion |
|---|------|------|--------------------------------------|
| G1 ≥ 90                                 | 4314 | 55.5 | 54.6- 56.8                           |
| G2 60–89                                | 2633 | 33.9 | 32.7- 34.8                           |
| G3a 45–59                               | 468  | 6.0  | 5.5- 6.6                             |
| G3b 30–44                               | 188  | 2.4  | 2.1- 2.8                             |
| G4 15–29                                | 113  | 1.5  | 1.2- 1.7                             |
| G5 ≤ 15                                 | 52   | 0.7  | 0.5- 0.9                             |

baseline data for future research and policy decisions. Further, the comparison of MDRD and CKD-EPI formula for eGFR estimation showed that the latter might be more applicable in screening “normal” population. The age and sex standardized prevalence of eGFR less than 60 mL/min/1.73 m<sup>2</sup> in this population of adults aging more than 18 years was 10.6%. Finally, Bayesian model estimate shows that UPCR > 150 as the most suitable test to detect renal damage in this endemic settings.

Interpretation of our results should be done with the limitations inherited in the design we used. First, the objective of the screening programme was not prevalence estimates and the sample selected is not using a probability sampling techniques. So the prevalence estimate based on the present study sample may not be generalizable to the source population. Secondly, these estimates are about screening test positivity, not about confirmed CKD, which require repeated samples within three months. Those who are having GFR < 60 ml/min/1.73 m<sup>2</sup> may be due to CKD or acute kidney injury or both. Since these participants are apparently healthy, probability of having AKI is low. Further, we have not differentiated CKD and CKDu in this study due to unavailability of detailed clinical history. Lastly, the proper validation procedure includes comparison with “Gold Standard” test, which we have not done in this study. Rather, we compared the predictive probability of eGFR using

**Table 3** Distribution of eGFR categories among 7768 apparently healthy CKD screening participants in Anuradhapura district by presence of proteinuria

| eGFR level (mL/min/1.73m <sup>2</sup> ) | Urine protein positive |      | Urine protein negative |      |
|---|------------------------|------|------------------------|------|
|   | n                      | %    | n                      | %    |
| Normal (> 90)                           | 746                    | 18.2 | 3359                   | 81.8 |
| Mildly decreased (60–89.9)              | 548                    | 21.4 | 2007                   | 78.6 |
| Moderately to severe decrease (30–59.9) | 240                    | 37.6 | 399                    | 62.4 |
| Severely decreased (15–29.9)            | 85                     | 75.9 | 27                     | 24.1 |
| Kidney failure < 15                     | 40                     | 78.4 | 11                     | 21.6 |

**Table 4** Performance of screening tests, in comparison to eGFR among CKD screening participants from Anuradhapura, Sri Lanka

|                                    | eGFR < 60 mL/min/1.73m <sup>2</sup> |      | eGFR > 90 mL/min/1.73m <sup>2</sup> |      |
|------------------------------------|-------------------------------------|------|-------------------------------------|------|
|                                    | n                                   | %    | n                                   | %    |
| <b>UACR</b>                        |                                     |      |                                     |      |
| > 30                               | 45                                  | 35.7 | 40                                  | 6.6  |
| = < 30                             | 81                                  | 64.3 | 564                                 | 93.4 |
| <b>UPCR</b>                        |                                     |      |                                     |      |
| > 150                              | 75                                  | 59.5 | 137                                 | 22.7 |
| = < 150                            | 51                                  | 40.5 | 467                                 | 77.3 |
| <b>Urine salicylic acid</b>        |                                     |      |                                     |      |
| Trace or above                     | 62                                  | 49.2 | 120                                 | 19.9 |
| Negative                           | 64                                  | 50.8 | 484                                 | 80.1 |
| <b>Urine dip stick<sup>a</sup></b> |                                     |      |                                     |      |
| Trace or above                     | 25                                  | 25.5 | 25                                  | 6.3  |
| Negative                           | 73                                  | 74.5 | 373                                 | 93.7 |

eGFR estimated glomerular filtration rate, CKD Chronic kidney disease, UACR Urine albumin creatinine ratio, UPCR Urine protein creatinine ratio. <sup>a</sup>for 230 patients, urine dip stick results were not available

urine based screening assays. The values reported should be interpreted as such.

Difference of MDRD and CKD-EPI formula in estimating eGFR is well known and studied. It is generally recommended for population as well as clinical use [18]. However, the differences in specific populations needs to be shown to get a good understanding about the population baseline data and interpretation. Our study shows the same pattern as previous studies done elsewhere. The eGFR estimation is based on age and sex, and the formula used has included these parameters to make sure that these changes are taken in to account. However, the population distribution data of eGFR by age and sex clearly shows that the cut off values for diagnosis of CKD may require adjustments. Using same threshold values for all age groups may lead to gross overestimation of CKD in this population, which might lead to issue in public health interventions. The National Kidney Foundation KDOQI guideline clearly states that age distribution of GFR values should be considered for threshold

**Table 5** Test characteristics of UPCR, USSA and UACR as screening tests to detect renal impairment; Bayesian Latent Class model analysis

| Test characteristic | UPCR             | USSA             | UACR             |
|---------------------|------------------|------------------|------------------|
| Sensitivity         | 61.8 (54.2–68.8) | 50.9 (43.6–58.1) | 35.3 (28.1–43.1) |
| Specificity         | 86.6 (82.5–90.9) | 87.5 (83.7–91.1) | 99.8 (98.3–100)  |
| PPV                 | 68.8 (58.3–79.6) | 66.1 (55.6–76.2) | 98.7 (90.2–100)  |
| NPV                 | 82.6 (77.1–86.9) | 78.8 (73.1–83.5) | 76.3 (70.0–81.5) |

values for CKD diagnosis [19]. The need for age base threshold values for CKD is discussed in literature [20] but yet to be implemented in health systems.

Leakage of albumin is caused by the involvement of the glomeruli in the initial stages of the disease due to common causes such as diabetes and hypertension. Evidence exists to suggest that the initial disease mechanism in CKDu primarily does not involve the glomeruli [11]. It is caused by chronic tubulointerstitial nephritis where proteinuria or albuminuria is not common as with conventional causes of CKD in initial stages. Among this study population where CKDu is the predominant disease, lack of microalbuminuria or proteinuria is challenging for early diagnosis in community settings. This study clearly demonstrated that standard cut off value looking for microalbuminuria (UACR > 30) is less sensitive to detect early cases. Multiple test will yield more results, however UPCR is recommended in addition to UACR as a screening test in this population where CKDu is common, specially because the available evidence [21–23] clearly suggests that the mortality and morbidity predictions needs combination of GFR and albuminuria/proteinuria. Hence, the ideal should be to use both eGFR and UACR/UPCR in this population.

## Conclusions

We recommend further studies to investigate age and sex specific adjustments for screening and diagnostic cutoff values for eGFR. UPCR and UACR should be use as screening tests in areas with high proportion of CKDu patients to increase the yield of the screening programme. However, combination of eGFR and UPCR/UACR should be the ideal screening method.

## Acknowledgments

We acknowledge the help given by Dr. Sarath Amunugama, Dr. Palitha Bandara, Dr. Asanga Ranasinghe, Mrs. K.D Sarala, Mrs. Anoma Premarathna, Mrs. Kanthi Premalatha, Mr. Anura Pubudukumara, Mr. R H Karunarathna and Mr. Priyantha Kumara during this study. Authors would like to thank the patients who participated in this study and the medical, nursing staff and volunteers for their assistance in recruitment of the participants.

## Authors' contributions

NK perceived the study, designed and carried out data collection, interpreted the data and participated in manuscript writing. RD was involved in the design stage, field work and data interpretation. MD, CJ, CK and TDS involved in field work, data collection, sample handling and database management, KW participated in data analysis, interpretation and manuscript preparation. SB involved in design, data analysis, interpretation and wrote the manuscript. All authors read and approved the final manuscript.

## Funding

None.

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Ethics approval and consent to participate

Informed verbal consent was obtained from participants who participated in sub-analysis (validation study) of urine samples. Verbal consent was obtained as this was a part of large population screening programme conducted as a routine service and no personal data were obtained. Ethical clearance for the validation study was obtained from the Ethics Review committee of University of Peradeniya.

## Consent for publication

Not relevant.

## Competing interests

None.

## Author details

<sup>1</sup>Teaching Hospital, Anuradhapura, Sri Lanka. <sup>2</sup>Teaching Hospital, Kandy, Sri Lanka. <sup>3</sup>Department of Parasitology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka. <sup>4</sup>Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka.

Received: 30 May 2018 Accepted: 19 July 2019

Published online: 05 August 2019

## References

- Levey AS, Coresh J. Chronic kidney disease. *Lancet*. 2012;379:165–80.
- Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and nutrition examination survey. *Am J Kidney Dis*. 2003;41:1–12.
- Otero A, de Francisco A, Gayoso P, García F, EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. *Nefrol. publicación of. la Soc. Española Nefrol* 2010;30:78–86.
- Study P. Assessing the impact of microalbuminuria. The second survey. *Trial Coord Center of Univ Med Cent Groningen*. 2005. Groningen (NL);2014.
- Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al. US Renal Data System 2012 Annual Data Report. *Am J Kidney Dis*. 2013;61:A7, e1–476.
- Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. *Lancet [Internet]*. 2013; 382:260–272. Available from: [https://doi.org/10.1016/S0140-6736\(13\)60687-X](https://doi.org/10.1016/S0140-6736(13)60687-X)
- Jha V. End-stage renal care in developing countries: the India experience. *Ren Fail*. 2004;26:201–8.
- Jayatilake N, Mendis S, Maheepala P, Mehta FR. Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country. *BMC Nephrol*. 2013;14:180.
- Athuraliya TNC, Abeysekera DTDJ, Amerasinghe PH, Kumarasiri PVR, Dissanayake V. Prevalence of chronic kidney disease in two tertiary care hospitals: high proportion of cases with uncertain aetiology. *Ceylon Med J*. 2009;54:23–5.
- Athuraliya NTC, Abeysekera TDJ, Amerasinghe PH, Kumarasiri R, Bandara P, Karunaratne U, et al. Uncertain etiologies of proteinuric-chronic kidney disease in rural Sri Lanka. *Kidney Int*. 2011;80:1212–21.
- Nanayakkara S, Komiya T, Ratnatunga N, Senevirathna STMLD, Harada KH, Hitomi T, et al. Tubulointerstitial damage as the major pathological lesion in endemic chronic kidney disease among farmers in north Central Province of Sri Lanka. *Environ Health Prev Med*. 2012;17:213–21.
- El Minshawy O. End-stage renal disease in the El-Minia governorate, upper Egypt: an epidemiological study. *Saudi J kidney Dis Transplant*. 2011;22: 1048–54.
- Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, Almeida AF, et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. *BMC Nephrol*. 2012;13:10.
- Moriguchi J, Inoue Y, Kamiyama S, Horiguchi M, Murata K, Sakuragi S, et al. N-acetyl-beta-D-glucosaminidase (NAG) as the most sensitive marker of tubular dysfunction for monitoring residents in non-polluted areas. *Toxicol Lett*. 2009;190:1–8.
- Čvorišćec D. Early diagnosis of endemic nephropathy. *Clin Chim Acta*. 2000; 297:85–91.
- Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. NGAL meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-

associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis.* 2009;54:1012–24.

17. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl.* 2013;3:1–150.
18. Levey AS, Inker LA, Coresh J. GFR Estimation: From Physiology to Public Health. *Am. J. Kidney Dis.* [Internet]. 2014 [cited 2017 Dec 5];63:820–34. Available from: [https://www.ajkd.org/article/S0272-6386\(13\)01634-X/fulltext](https://www.ajkd.org/article/S0272-6386(13)01634-X/fulltext).
19. Group KDIGO (KDIGO) CW. KDIGO 2012 clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl* 2013;3:4–4.
20. Delanaye P, Glassock RJ, Pottel H, Rule AD. An age-calibrated definition of chronic kidney disease: rationale and benefits. *Clin Biochem Rev* [Internet] The Australian Association of Clinical Biochemists. 2016;37:17–26 Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810758/>.
21. Van Der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int.* 2011.
22. Gansevoort RT, Matsushita K, Van Der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int.* 2011.
23. Gutiérrez OM, Khodneva YA, Muntner P, Rizk DV, McClellan WM, Cushman M, et al. Association between urinary albumin excretion and coronary heart disease in black vs white adults. *JAMA - J Am Med Assoc.* 2013.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)





## Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

[onlineservice@springernature.com](mailto:onlineservice@springernature.com)